India, Nov. 6 -- The company is a pharmaceutical formulations company focused on research and development, manufacturing and marketing of differentiated products, complex generics and drug-device combinations. The company primarily serves regulated markets, including the United States.

The Nifty 50 traded at 24,559.75, up by 0.04%, while the Sensex gained to 79,584.34, up by 3.5% on Friday. The shares of Rubicon Research are currently trading 1,649.70, down by 5.24%. The company has a market capitalisation of Rs. 27,305.68 crore. The stock's 52 week high is Rs. 1,899.00 and its 52 week low is Rs. 609.25. In the past 6 months, the stock has delivered a return of 64.76%.

What's the News? Rubicon Research announced its consolidated Q2 FY...